Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.97
- Piotroski Score 7.00
- Grade Neutral
- Symbol (NVS)
- Company Novartis AG
- Price $115.62
- Changes Percentage (-0.09%)
- Change -$0.1
- Day Low $115.28
- Day High $116.32
- Year High $120.92
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 09/24/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $118.00
- High Stock Price Target $121.00
- Low Stock Price Target $108.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.40
- Trailing P/E Ratio 23.94
- Forward P/E Ratio 23.94
- P/E Growth 23.94
- Net Income $14.85 B
Income Statement
Quarterly
Annual
Latest News of NVS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To 'Get The Attention Of Investors'
Jim Cramer advocates for financial literacy in high schools, emphasizing the importance of understanding money. He offers advice to young investors, promoting early investing and risk-taking. Novartis...
By Yahoo! Finance | 1 week ago -
Is Novartis AG (NVS) the Best Cancer Stock to Buy Now?
A list of the 10 Best Cancer Stocks includes Novartis AG as a top contender in the oncology market, set to reach over $470 billion by 2032. Novartis focuses on innovation in oncology and recently acqu...
By Yahoo! Finance | 1 week ago -
Novartis AG (NVS): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
Novartis AG (NYSE:NVS) is a Swiss pharma giant known for drugs like Scemblix and Kisqali. It ranks 4th among cheap pharmaceutical stocks. Its success hinges on innovative drugs and strategic marketing...
By Yahoo! Finance | 2 weeks ago
